Logo image of ETNB

89BIO INC (ETNB) Stock Fundamental Analysis

NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD

9.21  -0.01 (-0.11%)

After market: 9.12 -0.09 (-0.98%)

Fundamental Rating

2

Taking everything into account, ETNB scores 2 out of 10 in our fundamental rating. ETNB was compared to 571 industry peers in the Biotechnology industry. While ETNB seems to be doing ok healthwise, there are quite some concerns on its profitability. ETNB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ETNB had negative earnings in the past year.
ETNB had a negative operating cash flow in the past year.
In the past 5 years ETNB always reported negative net income.
ETNB had a negative operating cash flow in each of the past 5 years.
ETNB Yearly Net Income VS EBIT VS OCF VS FCFETNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

The Return On Assets of ETNB (-63.05%) is worse than 60.78% of its industry peers.
ETNB has a Return On Equity (-76.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA -63.05%
ROE -76.42%
ROIC N/A
ROA(3y)-43.73%
ROA(5y)-42.94%
ROE(3y)-55.08%
ROE(5y)-50.7%
ROIC(3y)N/A
ROIC(5y)N/A
ETNB Yearly ROA, ROE, ROICETNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

ETNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETNB Yearly Profit, Operating, Gross MarginsETNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

ETNB has more shares outstanding than it did 1 year ago.
ETNB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ETNB has an improved debt to assets ratio.
ETNB Yearly Shares OutstandingETNB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ETNB Yearly Total Debt VS Total AssetsETNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

ETNB has an Altman-Z score of 5.86. This indicates that ETNB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.86, ETNB belongs to the top of the industry, outperforming 81.64% of the companies in the same industry.
ETNB has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
ETNB's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. ETNB is outperformed by 66.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 5.86
ROIC/WACCN/A
WACCN/A
ETNB Yearly LT Debt VS Equity VS FCFETNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 11.66 indicates that ETNB has no problem at all paying its short term obligations.
ETNB has a Current ratio of 11.66. This is amongst the best in the industry. ETNB outperforms 83.96% of its industry peers.
A Quick Ratio of 11.66 indicates that ETNB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.66, ETNB belongs to the best of the industry, outperforming 84.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 11.66
ETNB Yearly Current Assets VS Current LiabilitesETNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ETNB have decreased strongly by -46.23% in the last year.
EPS 1Y (TTM)-46.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-208.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.74% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-62.39%
EPS Next 2Y-14.7%
EPS Next 3Y-11.82%
EPS Next 5Y4.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETNB Yearly Revenue VS EstimatesETNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ETNB Yearly EPS VS EstimatesETNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ETNB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ETNB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETNB Price Earnings VS Forward Price EarningsETNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETNB Per share dataETNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as ETNB's earnings are expected to decrease with -11.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.7%
EPS Next 3Y-11.82%

More info and screens

0

5. Dividend

5.1 Amount

ETNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

89BIO INC

NASDAQ:ETNB (2/26/2025, 4:58:08 PM)

After market: 9.12 -0.09 (-0.98%)

9.21

-0.01 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-19 2025-03-19/amc
Inst Owners100.95%
Inst Owner Change-97.51%
Ins Owners1.33%
Ins Owner Change18.2%
Market Cap1.22B
Analysts82.67
Price Target31.28 (239.63%)
Short Float %6.45%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.52%
Min EPS beat(2)-112.45%
Max EPS beat(2)17.4%
EPS beat(4)2
Avg EPS beat(4)-27.21%
Min EPS beat(4)-112.45%
Max EPS beat(4)17.4%
EPS beat(8)4
Avg EPS beat(8)-10.76%
EPS beat(12)7
Avg EPS beat(12)-5.3%
EPS beat(16)8
Avg EPS beat(16)-5.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.26%
PT rev (3m)1.8%
EPS NQ rev (1m)2%
EPS NQ rev (3m)2%
EPS NY rev (1m)0.97%
EPS NY rev (3m)-32.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 3.22
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.05%
ROE -76.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.73%
ROA(5y)-42.94%
ROE(3y)-55.08%
ROE(5y)-50.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.66
Quick Ratio 11.66
Altman-Z 5.86
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.43%
Cap/Depr(5y)202.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-208.89%
EPS Next Y-62.39%
EPS Next 2Y-14.7%
EPS Next 3Y-11.82%
EPS Next 5Y4.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-108.16%
EBIT Next 3Y-37.21%
EBIT Next 5YN/A
FCF growth 1Y-241.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-241.16%
OCF growth 3YN/A
OCF growth 5YN/A